Domain Therapeutics

Domain Therapeutics is a pharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-protein coupled receptors (GPCRs), one of the best drug targets. Domain Therapeutics is utilizing its innovative and proprietary technology platform, DTect-All™, to identify orthosteric and allosteric ligands of GPCRs, including so-called Silent Allosteric Modulators (SAMs), which represent a unique source of compounds that standard technologies cannot discover. The company aims to identify and develop a small molecule candidate drug capable of modulating neurotransmitter levels in the brain to treat neurodegenerative diseases such as Parkinson's Disease and Alzheimer's Disease.